RPRX Key Statistics, Chart & Performance
The current stock price of RPRX is 39.55 USD. In the past month the price increased by 3.24%. In the past year, price increased by 28.62%.
RPRX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to RPRX. When comparing the yearly performance of all stocks, RPRX is one of the better performing stocks in the market, outperforming 78.58% of all stocks.
RPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to RPRX. While RPRX has a great profitability rating, there are some minor concerns on its financial health.
RPRX Financial Highlights
Over the last trailing twelve months RPRX reported a non-GAAP Earnings per Share(EPS) of 4.11. The EPS increased by 0.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 32.55% | ||
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| Debt/Equity | 1.34 |
RPRX Forecast & Estimates
14 analysts have analysed RPRX and the average price target is 46.34 USD. This implies a price increase of 17.17% is expected in the next year compared to the current price of 39.55.
For the next year, analysts expect an EPS growth of 17.31% and a revenue growth 16.23% for RPRX
RPRX Ownership
RPRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.22 | 981.68B | ||
| JNJ | JOHNSON & JOHNSON | 21.07 | 526.82B | ||
| MRK | MERCK & CO. INC. | 12.35 | 270.12B | ||
| PFE | PFIZER INC | 8.02 | 145.84B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.42 | 112.50B | ||
| ZTS | ZOETIS INC | 19.66 | 54.93B | ||
| VTRS | VIATRIS INC | 5.52 | 14.81B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.55 | 12.19B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.94B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 5.38B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.31B |
Related stock screener links
About RPRX
Company Profile
Royalty Pharma Plc engages in the provision of drug development services. The company is headquartered in New York City, New York and currently employs 99 full-time employees. The company went IPO on 2020-06-16. The firm collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The company funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates.
Company Info
ROYALTY PHARMA PLC- CL A
110 East 59th Street
New York City NEW YORK 10022 US
CEO: Pablo Legorreta
Employees: 99
Phone: 12128830200
ROYALTY PHARMA PLC- CL A / RPRX FAQ
Can you describe the business of ROYALTY PHARMA PLC- CL A?
Royalty Pharma Plc engages in the provision of drug development services. The company is headquartered in New York City, New York and currently employs 99 full-time employees. The company went IPO on 2020-06-16. The firm collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The company funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates.
What is the current price of RPRX stock?
The current stock price of RPRX is 39.55 USD. The price decreased by -0.43% in the last trading session.
Does ROYALTY PHARMA PLC- CL A pay dividends?
ROYALTY PHARMA PLC- CL A (RPRX) has a dividend yield of 2.37%. The yearly dividend amount is currently 0.63.
What is the ChartMill rating of ROYALTY PHARMA PLC- CL A stock?
RPRX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Would investing in ROYALTY PHARMA PLC- CL A be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RPRX.
What is the employee count for RPRX stock?
ROYALTY PHARMA PLC- CL A (RPRX) currently has 99 employees.
Can you provide the market cap for ROYALTY PHARMA PLC- CL A?
ROYALTY PHARMA PLC- CL A (RPRX) has a market capitalization of 22.83B USD. This makes RPRX a Large Cap stock.